Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies

Lung

Volumn 190, Issue 4, 2012, Pages 451-458

  Fahim, Ahmed ^a   Chong, Mei C ^b   Crooks, Michael G ^a   Hart, Simon P ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Antiendothelial antibodies; Antiepithelial antibodies; Idiopathic pulmonary fibrosis; Immunofluorescence; Interstitial lung disease

Indexed keywords

CARBON MONOXIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

AGED; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBROSING ALVEOLITIS; FLUORESCENCE MICROSCOPY; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LUNG ALVEOLUS EPITHELIUM; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; PATHOGENESIS; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL;

AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; EPITHELIAL CELLS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PULMONARY ALVEOLI; PULMONARY DIFFUSING CAPACITY; RESPIRATORY FUNCTION TESTS; VITAL CAPACITY;

EID: 84864332317     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9390-z     Document Type: Article

References (37)

1. Lynch JP III, Wurfel M, Flaherty K, White E, Martinez F, Travis W, Raghu G (2001) Usual interstitial pneumonia. Semin Respir Crit Care Med 22(4):357-386
2. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA (2005) Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 127(1):171-177 (Pubitemid 41724573)
3. King TE Jr, Behr J, Brown KK, Du Bois RM, Lancaster L, de Andrade JA, Stahler G, Leconte I, Roux S, Raghu G (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75-81
4. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Sch-wartz DA, King TE Jr (2004) A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350(2):125-133 (Pubitemid 38056223)
5. Raghu G, Brown KK, Costabel U, Cottin V, Du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, Mc Dermott L, Fatenejad S (2008) Treatment of idiopathic pulmonary fibrosis with eta-nercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178(9):948-955
6. Carrington CB, Gaensler EA, Coutu RE, Fitz Gerald MX, Gupta RG (1978) Natural history and treated course of usual and des-quamative interstitial pneumonia. N Engl J Med 298(15): 801-809 (Pubitemid 8313452)
7. Katzenstein AA, Askin FB (1982) Surgical pathology of non-neoplastic lung disease. Major Probl Pathol 13:1-430
8. Feghali-Bostwick CA, Tsai CG, Valentine VG, Kantrow S, Stoner MW, Pilewski JM, Gadgil A, George MP, Gibson KF, Choi AM, Kaminski N, Zhang Y, Duncan SR (2007) Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immu-nol 179(4):2592-2599
9. Fujita J, Dobashi N, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Okada H, Takahara J (1999) Ele-vation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 177(5):311-319 (Pubitemid 29420469)
10. Fujita J, Takeuchi T, Dobashi N, Ohtsuki Y, Tokuda M, Takahara J (1999) Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis. Ann Rheum Dis 58(12):770-772
11. Erlinger R, Rauh G, Behr J, Schumacher U, Welsch U, Zollner N (1991) Similar frequency of autoantibodies against pneumocytes type II and Clara cells in patients with interstitial lung diseases and healthy persons. Klin Wochenschr 69(7):297-302
12. Meliconi R, Bestagno M, Sturani C, Negri C, Galavotti V, Sala C, Facchini A, Ciarrocchi G, Gasbarrini G, Astaldi Ricotti GC (1989) Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease. Clin Exp Immunol 76(2):184-189 (Pubitemid 19150386)
13. Meliconi R, Negri C, Borzi RM, Facchini A, Sturani C, Fasano L, Fabbri M, Astaldi Ricotti GC (1993) Antibodies to topoisomerase II in idiopathic pulmonary fibrosis. Clin Rheumatol 12(3): 311-315 (Pubitemid 23306864)
14. Wallace WA, Roberts SN, Caldwell H, Thornton E, Greening AP, Lamb D, Howie SE (1994) Circulating antibodies to lung pro-tein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 49(3):218-224 (Pubitemid 24117447)
15. Taille C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, Barrientos L, Mailleux A, Cigna N, Tubach F, Marchal-Somme J, Soler P, Chollet-Martin S, Crestani B (2011) Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(6):759-766
16. American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) Review 234 refs. Am J Respir Crit Care Med 161(2 Pt 1):646-664
17. Kim JH, Jang YS, Eom KS, Hwang YI, Kang HR, Jang SH, Kim CH, Park YB, Lee MG, Hyun IG, Jung KS, Kim DG (2007) Transforming growth factor beta1 induces epithelial-to-mesenchymal transition of A549 cells. J Korean Med Sci 22(5):898-904
18. Strieter RM (2005) Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 128(5 Suppl 1):526S-532S
19. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Tokuda M, Hojo S, Bandou S, Ueda Y, Takahara J (2000) Circulating cytokeratin 8: anti-cytokeratin 8 antibody immune complexes in sera of patients with pulmonary fibrosis. Respiration 67(4):397-401 (Pubitemid 30666001)
20. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Yamadori I, Yoshi-nouchi T, Ueda R, Bandoh S, Kamei T, Nishioka M, Ishida T, Takahara J (2000) Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 178(3):171-179 (Pubitemid 30489905)
21. Dobashi N, Fujita J, Ohtsuki Y, Yamadori I, Yoshinouchi T, Kamei T, Takahara J (1999) Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneu-monia. Eur Respir J 14(3):574-578 (Pubitemid 29479721)
22. Fujita J, Bandoh S, Ohtsuki Y, Dobashi N, Hiroi M, Takeuchi T, Fukunaga Y, Miyaue H, Onishi S, Ishida T, Takahara J (2000) The role of anti-epithelial cell antibodies in the pathogenesis of bilateral radiation pneumonitis caused by unilateral thoracic irradiation. Respir Med 94(9):875-880
23. Fujita J, Ohtsuki Y, Bandoh S, Takashima H, Ueda Y, Wu F, Tojo Y, Kubo A, Ishida T (2004) Elevation of cytokeratin 19 fragment (CYFRA 21-1) in serum of patients with radiation pneumonitis: possible marker of epithelial cell damage. Respir Med 98(4):294-300 (Pubitemid 38443688)
24. Ward PA (1979) Immune complex injury of the lung. Am J Pathol 97(1):85-92
25. Magro CM, Ross P, Marsh CB, Allen JN, Liff D, Knight DA, Waldman WJ, Cowden DJ (2007) The role of anti-endothelial cell antibody-mediated microvascular injury in the evolution of pulmonary fibrosis in the setting of collagen vascular disease. Am J Clin Pathol 127(2):237-247 (Pubitemid 46797181)
26. Magro CM, Waldman WJ, Knight DA, Allen JN, Nadasdy T, Frambach GE, Ross P, Marsh CB (2006) Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 67(4-5):284-297 (Pubitemid 43729356)
27. Magro CM, Allen J, Pope-Harman A, Waldman WJ, Moh P, Rothrauff S, Ross P Jr (2003) The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol 119(4):556-567 (Pubitemid 37046407)
28. Bellon B, Bernaudin JF, Mandet C, Chamak B, Kuhn J, Druet P (1982) Immune complex-mediated lung injury produced by horseradish peroxidase (HRP) and anti-HRP antibodies in rats. Am J Pathol 107(1):16-24 (Pubitemid 12153220)
29. Dall'Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S (1988) Study of immune complexes in bronchoalveolar lavage fluids. Respiration 54(Suppl 1):36-41
30. Dreisin RB, Schwarz MI, Theofilopoulos AN, Stanford RE (1978) Circulating immune complexes in the idiopathic intersti-tial pneumonias. N Engl J Med 298(7):353-357 (Pubitemid 8295553)
31. Haslam PL, Thompson B, Mohammed I, Townsend PJ, Hodson ME, Holborow EJ, Turner-Warwick M (1979) Circulating immune complexes in patients with cryptogenic fibrosing alve-olitis. Clin Exp Immunol 37(3):381-390 (Pubitemid 9257774)
32. Bournazos S, Bournazou I, Murchison JT, Wallace WA, Mc Farlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP (2010) Fcgamma receptor IIIb (CD16b) polymorphisms are associated with susceptibility to idiopathic pulmonary fibrosis. Lung 188(6):475-481
33. Bournazos S, Grinfeld J, Alexander KM, Murchison JT, Wallace WA, Mc Farlane P, Hirani N, Simpson AJ, Dransfield I, Hart SP (2010) Association of Fcgamma R IIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. BMC Pulm Med 10:51
34. Wallace WA, Schofield JA, Lamb D, Howie SE (1994) Locali-sation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis. Thorax 49(11):1139-1145 (Pubitemid 24339825)
35. Marrack P, Kappler J, Kotzin BL (2001) Autoimmune disease: why and where it occurs. Nat Med 7(8):899-905 (Pubitemid 32756426)
36. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, Du Bois RM, Wells AU (2010) Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35(4):830-836
37. Takabatake N, Arao T, Sata M, Abe S, Inoue S, Shibata Y, Takeishi Y, Kubota I (2005) Involvement of pulmonary endo-thelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 32(2):221-228 (Pubitemid 40248494)